Furthermore, the study sheds light on potential avenues of clinical investigation of anti-tau therapies by showing how targeting different tau processes (transport or local production) at different times during the AD continuum may be essential for effective intervention. The gene discussed is MAPT; the disease is Alzheimer disease.